Celldex Presents Data Demonstrating Barzolvolimab Improves Chronic Spontaneous Urticaria Independent of Baseline Immunoglobulin E levels in Phase 2 Study at EADV Congress 2025
Celldex Therapeutics, Inc. (CLDX)
Last celldex therapeutics, inc. earnings: 11/12 08:01 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.celldex.com
Company Research
Source: GlobeNewswire
HAMPTON, N.J., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today new data demonstrating rapid and strong efficacy regardless of baseline immunoglobulin E (IgE) levels in patients with chronic spontaneous urticaria (CSU), an immune-related condition driven by mast cell activation. Barzolvolimab specifically targets mast cells by binding the receptor tyrosine kinase KIT with high specificity and potently inhibiting its activity, which is required for mast cell function and survival. The data were presented in an oral e-poster presentation (EPS02.09) at the EADV Congress 2025 by Martin Metz, M.D., Professor, Department of Dermatology and Allergy, Head of Translation Research and Deputy Head of Clinical Trials at Charité – Universitätsmedizin in Berlin and the lead investigator of the study. “These data reinforce that mast cells are important drivers of CSU and that barzolvolimab, with its novel mechanism of action, has significant potential to be a meaningful t
Show less
Read more
Impact Snapshot
Event Time:
CLDX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CLDX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CLDX alerts
High impacting Celldex Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CLDX
News
- Celldex Therapeutics (NASDAQ:CLDX) had its price target lowered by analysts at Barclays PLC from $25.00 to $21.00. They now have an "underweight" rating on the stock.MarketBeat
- Celldex Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswire
- Celldex Announces Appointment of Teri Lawver as Chief Commercial OfficerGlobeNewswire
- Celldex to Present at Upcoming Investor ConferencesGlobeNewswire
- Celldex Presents Additional Positive Data Demonstrating Barzolvolimab’s Ability to Drive Rapid, Profound and Durable Complete Urticaria Control in Phase 2 Chronic Spontaneous Urticaria (CSU) StudyGlobeNewswire
CLDX
Earnings
- 11/10/25 - Miss
CLDX
Sec Filings
- 12/4/25 - Form 144
- 11/17/25 - Form 4
- 11/14/25 - Form SCHEDULE
- CLDX's page on the SEC website